Advertisement

Topics

Pepperl+Fuchs GmbH Company Profile

00:30 EST 23rd November 2017 | BioPortfolio

Pepperl+Fuchs designs, produces and distributes electronic sensors and components for the global Automation market. Continuous innovation, enduring quality, and steady growth guarantees continued success.
The Factory Automation Division is a leading manufacturer of a wide range of industrial inductive, photoelectric and ultrasonic sensors. Complementing this line of mostly binary sensors, we also offer complex sensors, identification and communication systems.

The Process Automation Division is the market leader for intrinsically safe components and intrinsically safe decentralized peripherals. Our products easily connect with Fieldbus Components and allow the simple design of Fieldbus Topology.

Location

Königsberger Allee 87
Mannheim
68307
Germany

Contact

Phone: 49 (0)621 776-0
Fax: 49 (0)621 776-1000
Email: info@de.pepperl-fuchs.com


News Articles [136 Associated News Articles listed on BioPortfolio]

Global and Asia Cable Gland Plugs Market Status and Future Forecast 20132023 [Report Updated: 07112017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Global and Asia Industrial Monitor Market Status and Future Forecast 20132023 [Report Updated: 19102017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Global and Asia Explosion Proof Equipment Market Status and Future Forecast 20132023 [Report Updated: 17102017] Prices from USD $3000

SummaryKey Content of Chapters Including and can be customizedPart 1:Market Overview, Development, and Segment by Type, Application RegionPart 2:Global Market by company, Type, Application RegionPar...

Royalties under patent licence agreements: can they remain payable even if the licensed patents(s) are revoked or not practised? Lessons from Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH

Précis In its recent decision in Genentech Inc v Hoechst GmbH & Sanofi-Aventis Deutschland GmbH (7 July 2016), the Court of Justice of the EU (“CJEU”) has ruled that an obligati...

Global Cable Gland Plugs Market Research Report 20112023 [Report Updated: 05112017] Prices from USD $2280

SummaryThe global Cable Gland Plugs market will reach xxx Million USD in 2017 with CAGR xx% 20182023. The objective of report is to define, segment, and project the market on the basis of product type...

CytomX Therapeutics Appoints Charles S. Fuchs, M.D., MPH to Board of Directors

SAN FRANCISCO, Oct. 24, 2017 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq:CTMX), a biopharmaceutical company developing investigational Probody™ therapeutics for the treatment of c...

Endocyte licenses radioligand prostate cancer therapy from ABX GMBH

Endocyte Inc. received exclusive global rights to the radioligand therapeutic PSMA617 (177LuPSMA617) from ABX GMBH.

DGAP-News: GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institutional Sales, begleitet und waren signifikant

GBC Kapital GmbH: Erfolgreich abgeschlossene Kapitalmaßnahme der SYGNIS AG - beide Kapitalerhöhungen wurden von der GBC Kapital GmbH und der MC Services AG, jeweils als Co-Lead Manager Institution.....

PubMed Articles [38 Associated PubMed Articles listed on BioPortfolio]

Descemetorhexis Without Grafting for Fuchs Endothelial Dystrophy-Supplementation With Topical Ripasudil.

To report the safety and efficacy of descemetorhexis without grafting as a primary intervention in Fuchs dystrophy, and the use of a ROCK inhibitor, ripasudil as a salvage agent in failing cases.

Elimination of Anterior Corneal Steepening With Descemet Membrane Endothelial Keratoplasty in a Patient With Fuchs Dystrophy and Keratoconus: Implications for IOL Calculation.

To report a case of coexistent Fuchs endothelial corneal dystrophy (FECD) and keratoconus (KCN) in which there was normalization of corneal topography after Descemet membrane endothelial keratoplasty ...

Descemetorhexis Without Graft Placement for the Treatment of Fuchs Endothelial Dystrophy: Preliminary Results and Review of the Literature.

To report our preliminary experience with a central descemetorhexis without graft placement in Fuchs endothelial corneal dystrophy (FECD) and to review the existing literature on the topic.

Dark Endothelial Spots After Descemet Membrane Endothelial Keratoplasty May Appear as Recurrent Fuchs Dystrophy or Herald Graft Failure or Rejection.

To evaluate the clinical significance of dark spots in the donor endothelial cell layer as observed with specular microscopy, in patients who underwent Descemet membrane endothelial keratoplasty (DMEK...

Sustained Activation of the Unfolded Protein Response Induces Cell Death in Fuchs' Endothelial Corneal Dystrophy.

The unfolded protein response (UPR) is believed to play a role in the pathogenesis of Fuchs' endothelial corneal dystrophy (FECD). The purpose of this study was to investigate whether unfolded protein...

Clinical Trials [48 Associated Clinical Trials listed on BioPortfolio]

Fuchs' Torsional Phaco Study

The primary objective is to compare the effect of torsional phacoemulsification and longitudinal phacoemulsification on central and peripheral corneal thickness/volume after cataract surge...

DMEK Versus DSAEK Study

The purpose of this study is to determine whether corneal transplantation by Descemet Membrane Endothelial Keratoplasty more favourable and cost-effective is compared to Descemet Stripping...

A Study Investigating the Safety, Tolerability, and Efficacy of MTP-131 Topical Ophthalmic Solution for the Treatment of Fuchs' Corneal Endothelial Dystrophy (FCED)

This is a Phase 1/2, prospective, randomized, double-masked, vehicle controlled, paired-eye study in approximately 16 subjects to evaluate safety, tolerability and efficacy of MTP-131 opht...

Bioequivalence Study Comparing Two Test Products With One Reference Product, All Containing 5 mg Yohimbine

- Type: Bioequivalence study in male healthy volunteers, therapeutical indication (erectile disfunction) not studied - Products, dosage, and route of administration: ...

Bioequivalence Study of Linagliptin From Prevaglip 5 mg Tablets(Eva Pharma, Egypt) and Trajenta 5 mg Tablets (Boehringer Ingelheim International GmbH, Germany)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Linagliptin from Prevaglip 5 mg tablets(Eva pharma for Pharmaceuticals & Me...

Companies [523 Associated Companies listed on BioPortfolio]

Pepperl+Fuchs GmbH

Pepperl+Fuchs designs, produces and distributes electronic sensors and components for the global Automation market. Continuous innovation, enduring quality, and steady growth guarantees continued succ...

Chemie-Kontor GmbH

Chemie-Kontor GmbH trades with chemical specialities for customers in Pharma-, Agro-, Cosmetics and Nutrition Industries and offers a broad range of services. Chemie-Kontor GmbH is agent for: Amberger...

OctreoPharm Sciences GmbH

OctreoPharm Sciences GmbH, located in Berlin (Germany) is a privately held clinical development company focusing on radiopharmaceuticals for the diagnosis and therapeutic control ...

Praher Beteiligungs GmbH

The vision of the company founder Ludwig Praher to produce better and better products of high-grade plastics was the basis for sound growth. Under the direction of Ing. Winfried Praher and Ewald Prahe...

Ormecon GmbH

Ormecon GmbH, with its location in Ammersbek/Germany, is the headquarter of Ormecon International. Ormecon GmbH was originally founded as "Ormecon Chemie GmbH & Co. KG" in 1996, as a 100% subsidiary o...

More Information about "Pepperl+Fuchs GmbH" on BioPortfolio

We have published hundreds of Pepperl+Fuchs GmbH news stories on BioPortfolio along with dozens of Pepperl+Fuchs GmbH Clinical Trials and PubMed Articles about Pepperl+Fuchs GmbH for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pepperl+Fuchs GmbH Companies in our database. You can also find out about relevant Pepperl+Fuchs GmbH Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record